Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment
Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement is for the investigational, potential first-in-class radioenhancer NBTXR3.
NBTXR3 is currently in several studies assessing its safety and efficacy, including the global phase 3 NANORAY-312 study which is evaluating the treatment for patients with locally advanced head and neck cancer. NBTXR3 is also being assessed for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for the treatment of metastatic cancers.
Under the terms of the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialisation of NBTXR3, in collaboration with the Interventional Oncology R&D Unit of Johnson & Johnson. Nanobiotix will receive near-term cash and operational support valued up to $60m, including an upfront cash licensing fee of $30m and regulatory and development support for study NANORAY-312 up to $30m, provided at Janssen’s discretion. […]
The post Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment appeared first on Pharmafile.
